S&P 5007,785.76▼0.2% Nasdaq26,729.16▼0.3% Dow53,732.41▼0.2% Russell 2K3,068.42▲0.5% 10-Yr4.70%+6bp VIX14.25−0.38 WTI$82.40▲1.4% Gold$4,432.00▲1.6% EUR/USD1.157▲0.4% BTC$78,412▼0.2% Nikkei68,309▲1.2%
At close · Fri, Aug 14, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›FDA approves daraxonrasib for pancreatic cancer after…

FDA approves daraxonrasib for pancreatic cancer after trial results

Reported · Written up by our desk · Previews

The New York Times reports the FDA has approved daraxonrasib, a pill intended to treat pancreatic cancer.

In a key clinical trial, patients who received daraxonrasib lived twice as long as patients who were treated with chemotherapy, according to the report.

← Newer storyScandium Canada returns assays up to 315 ppm at Crater Lake

More like this

EarningsWilliams-Sonoma stock holds key support after raised Q2 guidance
EarningsAlcoa breaks ground on Western Australia facility to extract gallium
EarningsOura Health targets about $16 billion valuation in US IPO
EarningsPhotronics beats fiscal Q3 expectations and raises guidance on AI demand
EarningsAbercrombie & Fitch shares rise after earnings beat and guidance lift

Sources

NYT BusinessF.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.